Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase-out of CFCs in epinephrine inhalers

This article was originally published in The Gray Sheet

Executive Summary

FDA proposes elimination of "essential use" designation that continues to allow use of polluting chlorofluorocarbons in metered dose inhalers for epinephrine - available over-the-counter for mild asthma. The agency "has tentatively concluded that there are no substantial technical barriers to formulating epinephrine as a product that does not release CFCs," FDA explains in a Sept. 20 announcement. Inhalers with CFCs would be phased out by the end of 2010 under the proposed rule, on which FDA will seek public comment
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT025290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel